Product Description
Syndax is developing Entinostat. Entinostat, is a selective, oral, once-weekly, class I HDAC inhibitor that has been studied in multiple solid tumors in combination with hormone therapy and several approved PD-1/PD-L1 antagonists. (Sourced from: https://syndax.com/pipeline/entinostat/)
Mechanisms of Action: HDAC Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Syndax
Company Location: WALTHAM MA 02451
Company CEO: Michael A. Metzger
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Japan, Sweden, United States
Active Clinical Trial Count: 8
Highest Development Phases
Phase 2: Breast Cancer|Colorectal Cancer|Lymphoma|Melanoma|Non-Small-Cell Lung Cancer|Renal Cell Carcinoma|Uveal Melanoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCT03179930 | P2 |
Active, not recruiting |
Lymphoma |
2025-06-01 |
|
| NA_00084192 | P2 |
Completed |
Non-Small-Cell Lung Cancer |
2023-04-04 |
|
| PEMDAC | P2 |
Completed |
Uveal Melanoma |
2023-01-31 |
|
| HCRN GU17-289 | P2 |
Active, not recruiting |
Renal Cell Carcinoma |
2023-01-20 |